News center_innoModel-Provide preclinical pharmacological services

Cn /En

News Center

——

Company news

Industry news

04-19

InnoModels' ELISpot Platform: A New Perspective on Cellular Immunity

With the continuous development of biotechnology, people's understanding of cellular immunity mechanism is getting deeper and deeper. As a highly sensitive and specific immunoassay technology, the InnoModels Biotechnology ELISpot platform provides researchers and clinicians with a new perspective to explore cellular immune responses in depth.

04-18

InnoModels Biotechnology: What are the characteristics of T-cell-mediated killing experimental platform?

With the deepening of cancer immunotherapy research, T-cell-mediated killing experimental platform has become a major research hotspot in the field of scientific research. Relying on its profound accumulation in biotechnology, InnoModels Biotechnology has successfully constructed a T-cell-mediated killing experimental platform, which has shown distinctive features and strong potential in the research of tumor immunotherapy.

04-18

InnoModels Biotechnology: ADCC Platform Features

With the continuous progress of science and technology, mankind's understanding of life sciences is deepening. In this process, by virtue of its excellent R&D strength and innovation ability, InnoModels Biotechnology has successfully built an ADCC (Antibody Dependent Cytotoxicity) in vitro killing experimental platform, which opens up a new path for the research and development of tumor immunotherapy.

04-17

InnoModels Biotechnology CDC In Vitro Immuno-Tumor Cell Co-Culture Killing Experimental Platform

With the rapid development in the field of cancer treatment, the therapeutic potential of immunotherapy, especially cytotoxic drugs (CDC), has received widespread attention. However, how to accurately assess the efficacy of CDC drugs in vivo and how to optimize the therapeutic regimen has been a challenge for researchers and pharmaceutical companies. To address this issue, InnoModels Biotechnology has developed a CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides a new powerful tool for tumor immunotherapy research.

< 1...27 28 29...62 >

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL: +86 15711355061
E-mail: xuyl@imodels.tech
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

InnoModels Biotechnology (Beijing) Co., Ltd

SEO

Business License